Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy

J Control Release. 2022 Mar:343:288-302. doi: 10.1016/j.jconrel.2022.01.040. Epub 2022 Jan 29.

Abstract

The therapeutic gain in loco-regionally advanced unresectable head and neck squamous cell carcinoma (HNSCC) is limited with the traditional use of concurrent chemoradiotherapy (CRT) owing to dose-limiting toxicities of systemic clinical radiosensitizers. Delivery through regional platforms is challenging due to limited drug permeation but allows spatio-temporal control of combinatorial regimens locally to overcome drug resistance. We address these challenges by developing biodegradable gellan- and lipid-based dual nanocarriers-in-ion-triggered porous mucoadhesive hydrogels for enhanced site-specific delivery of clinically relevant radiosensitizers i.e. cisplatin and paclitaxel. Interestingly, the nanoparticle-in-gel prolonged the tumor bioaccumulation of both the chemotherapeutic drugs with reduced systemic absorption, thereby improving in vivo efficacy which was confirmed by PET-CT imaging and safety as compared to systemic commercial formulations approved for HNSCC chemoradiotherapy. The nanoparticles facilitated intracellular radiosensitizer uptake and cell arrest to synergistically enhance radiation-induced DNA nicks and apoptosis. Our findings suggest the clinical potential of the present platform in the loco-regional management of HNSCC requiring curative CRT.

Keywords: Apoptosis; Chemoradiotherapy; Head and neck squamous cell carcinoma; Loco-regional; Nanoparticle-in-hydrogel; Synergistic radiosensitizers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Chemoradiotherapy / methods
  • Cisplatin
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Nanoparticles*
  • Positron Emission Tomography Computed Tomography
  • Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

  • Cisplatin